Floatz logo

Brimonidine

Recurrent Ovarian Cancer

AbbVieSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

524 Active assets in the Recurrent Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB
OTL-38
On Target Laboratories, LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Brimonidine is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
65 / 100
View asset →
prostate cancerDormant
B
Indicative ·
56 / 100
View asset →
Folate Receptor-Alpha PositiveDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →